Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Prof Nicholas Paton

Professor of Infectious Diseases

United Kingdom

Jump to: Affiliations Publications

Affiliations
Department of Clinical Research
Faculty of Infectious and Tropical Diseases

Selected Publications
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo, C; Mambule, IK; Musaazi, J; Sokhela, S; Mugerwa, H; Ategeka, G; Cresswell, F; Siika, A; Kosgei, J; Shah, R; Naidoo, L; Opiyo, K; Otike, C; Möller, K; Kaimal, A; Wambui, C; Van Eygen, V; Mohammed, P; Addo Boateng, F; PATON, NI; CARES trial team,;
2024
The Lancet. Infectious diseases
Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis: proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial.
PATON, NI; Gurumurthy, M; Lu, Q; Leek, F; Kwan, P; Koh, HW L; Molton, J; Mortera, L; Naval, S; Abu Bakar, Z; Pang, Y-K; Lum, L; Lim, TK; Cross, GB; Lekurwale, G; Choi, H; Au, V; Connolly, J; Hibberd, M; Green, JA; Pascolizumab Tuberculosis Trial Team
,;
2024
The Journal of infectious diseases
Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach.
CRyPTIC Consortium,;
2024
Nature communications
Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?
Cross, GB; O' Doherty, J; Chang, CC; Kelleher, AD; PATON, NI;
2023
The Journal of infectious diseases
Recent advances in the treatment of tuberculosis.
Motta, I; Boeree, M; Chesov, D; DHEDA, K; Günther, G; Horsburgh, CR; Kherabi, Y; Lange, C; Lienhardt, C; McIlleron, HM; PATON, NI; STAGG, HR; Thwaites, G; Udwadia, Z; Van Crevel, R; Velásquez, GE; Wilkinson, RJ; Guglielmetti, L; Study group on Mycobacteria (ESGMYC) of the Europe,;
2023
Clinical Microbiology and Infection
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis.
Sonnenkalb, L; Carter, JJ; Spitaleri, A; Iqbal, Z; Hunt, M; Malone, KM; Utpatel, C; Cirillo, DM; Rodrigues, C; Nilgiriwala, KS; Fowler, PW; Merker, M; Niemann, S; Comprehensive Resistance Prediction for Tuberculos,;
2023
The Lancet. Microbe
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Cross, GB; Sari, IP; Kityo, C; Lu, Q; Pokharkar, Y; Moorakonda, RB; Thi, H-N; Do, Q; Dalay, VB; Gutierrez, E; Balanag, VM; Castillo, RJ; Mugerwa, H; Fanusi, F; Kwan, P; Chew, KL; Paton, NI; ROSETTA trial team,;
2023
The Lancet. Infectious diseases
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
PATON, NI; Cousins, C; Suresh, C; Burhan, E; Chew, KL; Dalay, VB; Lu, Q; Kusmiati, T; Balanag, VM; Lee, SL; Ruslami, R; Pokharkar, Y; Djaharuddin, I; Sugiri, JJ R; Veto, RS; Sekaggya-Wiltshire, C; Avihingsanon, A; Sarin, R; Papineni, P; Nunn, AJ; Crook, AM; TRUNCATE-TB Trial Team,;
2023
The New England journal of medicine
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
CRyPTIC Consortium,;
2022
The European respiratory journal
High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer, V; Mandal, A; Dev, P; Merker, M; Barilar, I; Utpatel, C; Nilgiriwala, K; Rodrigues, C; Crook, DW; CRyPTIC Consortium,; Rasigade, J-P; Wirth, T; Mistry, N; Niemann, S;
2022
Genome medicine
See more information

Contact

United Kingdom